A spacer peptide that facilitates antigen presentation

By using spacer peptides based on the PLKW amino acid sequence and designing corresponding nucleic acid molecules, the problem of poor antigen presentation in personalized tumor mRNA vaccines was solved, resulting in a more efficient immune response and T cell activation.

CN120209073BActive Publication Date: 2025-09-23BEIJING LIKANG LIFE SCIENCES & TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510696562.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-05-28
Publication Date
2025-09-23
Estimated Expiration
2045-05-28

AI Technical Summary

Technical Problem

Existing spacer peptides have failed to effectively achieve efficient antigen presentation in personalized tumor mRNA vaccines, affecting the immune response. They may also bind to MHC molecules, be processed by the proteasome, or generate RNA secondary structures, affecting T cell activation.

Method used

Using a spacer peptide with the amino acid sequence PLKW, nucleic acid molecules were optimized to improve the translation and processing of antigenic peptides in dendritic cells, and the spacer peptide was encoded by nucleic acid molecules to prepare vaccines.

Benefits of technology

It significantly improved the immune efficacy of neoantigen vaccines in vivo, enhanced the processing and presentation capabilities of antigen peptides, avoided immune interference caused by inappropriate spacer peptides, and achieved better T cell activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120209073B_ABST
    Figure CN120209073B_ABST
Patent Text Reader

Abstract

This application relates to a spacer peptide that acts as a barrier between different antigens in vaccines. It can be efficiently cleaved by specific enzymes in vivo, releasing the antigens and enabling effective presentation of the antigens by antigen-presenting cells. This application also relates to synthetic nucleic acid molecules, uses of spacer peptides or nucleic acid molecules, and nucleic acid cancer vaccines.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Vaccine compositions and methods of use thereof

    CN102448491A

  • Personalized cancer vaccine epitope selection

    CN113365639A